Impact of new physics on B + L violation at colliders von Cerdeño, D G, Reimitz, P, Sakurai, K, amarit, C T

Volltext

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study von Montgomery, S A, Reimitz, P -E, Zivkov, M

Volltext

Potential of CMS as a high-energy neutrino scattering experiment von Foldenauer, P., Kling, F., Reimitz, P.

Volltext

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study von de Groot, Joris R, Weiss, Thomas W, Kelly, Peter, Monteiro, Pedro, Deharo, Jean Claude, de Asmundis, Carlo, López-de-Sá, Esteban, Waltenberger, Johannes, Steffel, Jan, Levy, Pierre, Bakhai, Ameet, Zierhut, Wolfgang, Laeis, Petra, Manu, Marius Constantin, Reimitz, Paul-Egbert, De Caterina, Raffaele, Kirchhof, Paulus

Volltext

Effectiveness and safety of edoxaban in atrial fibrillation patients from the ETNA-AF global registry von De Caterina, R, Wang, R, Shi, L, Pecen, L, Ye, X, Reimitz, P.-E, Chen, C, Unverdorben, M, Giugliano, R.P

Volltext

Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program von Yamashita, T, Wang, C.C, Kim, Y.-H, De Caterina, R, Kirchhof, P, Reimitz, P, Chen, C, Unverdorben, M, Koretsune, Y

Volltext

Recommended and non-recommended edoxaban dosing in patients with atrial fibrillation (AF): one-year clinical events from the Global ETNA-AF non-interventional study (NIS) von Chao, T.F, Kirchhof, P, Koretsune, Y, Yamashita, T, Unverdorben, M, Reimitz, P, Chen, C, De Caterina, R

Volltext

Edoxaban treatment in real-world practice is highly concordant with ESC atrial fibrillation guidelines: results from the non-interventional global ETNA-AF program von Morrone, D, Chen, C, Dinshaw, L, Jiang, W, Kim, Y.-H, Kirchhof, P, Koretsune, Y, Pecen, L, Reimitz, P.-E, Wang, C.-C, Yamashita, T, Unverdorben, M, De Caterina, R

Volltext

Temporal trend of clinical events in patients with atrial fibrillation on edoxaban therapy: results from the non-interventional global ETNA-AF program von Dinshaw, L, Chen, C, De Caterina, R, Jiang, W, Kim, Y.-H, Koretsune, Y, Morrone, D, Pecen, L, Reimitz, P.-E, Wang, C.-C, Yamashita, T, Unverdorben, M, Kirchhof, P

Volltext

PP.21.16: META-ANALYSIS OF OLMESARTAN-BASED SINGLE PILL COMBINATION VERSUS MONOTHERAPY FOR REDUCING BLOOD PRESSURE von Deedwania, P., Chavanu, K., Maa, J., Reimitz, P., Bakris, G.L.

Volltext

Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: is there a transatlantic difference? von Niklson, I.A, Reimitz, P.-E

Volltext

P4788One-year outcomes of elderly patients with atrial fibrillation: snapshot data from the global noninterventional program on edoxaban treatment in routine clinical practice in a... von Wang, C C, Kim, Y H, Brueggenjuergen, B, De Caterina, R, Kirchhof, P, Lee, B C, Levy, P, Rauer, H, Reimitz, P E, Unverdorben, M, Yamashita, T, Koretsune, Y

Volltext

P4785Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of th... von Kirchhof, P, Unverdorben, M, Koretsune, Y, Wang, C C, Kim, Y H, Brueggenjuergen, B, Lee, B C, Levy, P, Rauer, H, Reimitz, P E, Yamashita, T, De Caterina, R

Volltext

Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year re... von Morrone, D, Unverdorben, M, Chen, C, Dinshaw, L, Jiang, W, Kim, Y-H, Kirchhof, P, Koretsune, Y, Pecen, L, Reimitz, P-E, Wang, C-C, Yamashita, T, De Caterina, R

Volltext

Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program von Dinshaw, L, Unverdorben, M, Chen, C, De Caterina, R, Jiang, W, Kim, Y-H, Koretsune, Y, Morrone, D, Pecen, L, Reimitz, P-E, Wang, C-C, Yamashita, T, Kirchhof, P

Volltext

PP.07.16: META-ANALYSIS OF BLOOD PRESSURE REDUCTIONS WITH OLMESARTAN MEDOXOMIL IN CLINICAL COMPARISONS WITH ACTIVE CONTROLS IN PATIENTS WITH HYPERTENSION von Redon, J., Deedwania, P., Kario, K., Wang, J., Versteden, J., Reimitz, P.

Volltext

PP.07.01: META-ANALYSIS OF OLMESARTAN MEDOXOMIL MONOTHERAPY IN REDUCING BLOOD PRESSURE IN ELDERLY PATIENTS WITH HYPERTENSION von Redon, J., Weber, M.A., Wang, J.G., Chavanu, K., Maa, J., Reimitz, P.

Volltext

A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon) von Out, Henk J., Reimitz, Paul E., Coelingh Bennink, Herjan J.T.

Volltext

Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry von Brüggenjürgen, B, Schliephacke, T, Darius, H, De Caterina, R, Le Heuzey, J.Y, Pittrow, D, Reimitz, P.E, Schilling, R.J, Zamorano, J.L, Kirchhof, P

Volltext

Health State In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With The New Eq-5d-5l Questionnaire At Baseline And 12-Month Follow-Up: Prefer In Af Regist... von Brüggenjürgen, B, Schliephacke, T, Darius, H, De, Caterina R, Le, Heuzey J.Y, Reimitz, P.E, Schilling, R.J, Schwertfeger, M, Zamorano, J.L, Kirchhof, P

Volltext